Why Are CBD Rules Still Being Written?

CBD has spent years moving between the medicine cabinet, the wellness aisle and the fashion campaign. It appears in conversations about sleep, recovery and everyday calm, often alongside soft fabrics, muted color palettes and the promise of a more considered routine. But the regulatory picture behind cannabidiol remains less polished: in the United States, key questions about how CBD can be sold in foods and supplements have not been resolved into one clear, comprehensive federal system.

That gap is not simply a matter of government moving slowly. CBD sits at the intersection of several legal and commercial categories, including hemp, food, dietary supplements, cosmetics and drugs. The result is a patchwork of federal guidance, state rules and enforcement decisions. For brands and shoppers alike, understanding why CBD regulation is still evolving means separating what the law says from what marketing suggests.

The short version: Congress created a legal pathway for hemp, but that did not automatically create a full FDA framework for CBD products. Until lawmakers and regulators settle how CBD should be treated in common consumer goods, the rules will keep being written—in legislation, agency decisions and state-level requirements.

Hemp’s legal opening was not a complete CBD rulebook

The 2018 Farm Bill removed hemp, as defined by federal law, from the Controlled Substances Act. That change helped create a legal route for cultivating and selling hemp and hemp-derived ingredients, subject to the law’s definition and other applicable requirements. It also helped the CBD market grow quickly.

But legal hemp and federally approved CBD products are not interchangeable ideas. The Farm Bill did not establish a general approval for putting CBD into foods or marketing it as a dietary supplement. Nor did it settle every issue involving product safety, labeling, manufacturing or health claims. In other words, one important legal barrier changed, while the consumer-product questions remained.

This distinction can be easy to miss on a product page. “Hemp-derived” may describe the source of an ingredient; it does not, by itself, prove that a finished product is lawful in every category, safe for every person or supported by a particular health benefit. A phrase can be technically relevant and still leave the shopper without the details that matter.

Why the FDA framework is complicated

The Food and Drug Administration regulates products according to what they are and how they are intended to be used. A cosmetic, a food, a dietary supplement and a drug each face different legal requirements. CBD complicates that system because the agency has addressed cannabidiol in connection with an approved drug product, while the broader market has sought to sell CBD in everyday consumer formats.

The FDA has generally taken the position that existing federal law creates obstacles to marketing CBD as an ingredient in conventional foods or dietary supplements, including because CBD is the active ingredient in an approved drug and has been subject to substantial clinical investigations. The details matter, and the legal analysis can depend on product category and facts. The practical takeaway is more straightforward: there is no blanket FDA approval that makes all CBD oils, gummies, drinks or other ingestible products compliant simply because they are hemp-derived.

Regulatory uncertainty also reflects a real policy challenge. Agencies need evidence about safety, exposure, dosage, interactions and manufacturing consistency. CBD products vary widely in concentration and format, while consumers may use them alongside prescription medicines or other supplements. A workable FDA framework would need to address these differences without treating every product as identical.

What the current uncertainty can look like for shoppers

• Different rules for different product types: A topical product and an ingestible product may not face the same legal requirements.
• State-by-state variation: States can set additional restrictions or requirements, so a product’s availability may differ by location.
• Uneven testing information: Some brands publish batch-specific certificates of analysis; others provide limited or hard-to-find documentation.
• Marketing claims that outrun evidence: Words such as “calming,” “recovery” or “supports sleep” can imply benefits that deserve careful scrutiny.

The Congress pathway: what lawmakers still have to decide

Many stakeholders have argued that Congress needs to create a clearer pathway for CBD products, particularly ingestibles. That pathway could define which product categories may contain CBD, establish limits or conditions for use, set labeling expectations and clarify how FDA oversight should work. Any such system would also need to address age restrictions, manufacturing standards, adverse-event reporting and the role of state regulators.

There is no single consensus version of that policy. Some proposals emphasize access to hemp-derived products under defined conditions; others put greater weight on premarket review, safety evidence or tighter limits. Congress must weigh consumer access against the possibility of misleading claims and inconsistent product quality. It also has to decide how new rules would interact with the existing FDA framework rather than simply creating a parallel system.

That is why “Congress pathway” is more than a legislative catchphrase. It describes the unresolved question of how CBD moves from a fast-growing market with mixed rules into a regulated category with clearer responsibilities. Until legislation provides direction—or the FDA adopts a different approach within its authority—brands have to navigate a landscape where permission in one context does not necessarily translate to permission in another.

Wellness language has entered fashion and lifestyle branding

The regulatory debate is unfolding alongside a larger cultural shift: wellness language has become part of how fashion and lifestyle companies describe everyday life. The emphasis is less on a single, exceptional purchase and more on the routines surrounding work, movement, rest and getting dressed. PAGE Magazine might cover this crossover as a consumer-trust story as much as a style story: a wellness promise is also a claim that deserves evidence.

Brands such as lululemon have helped make movement, comfort and daily practice central to lifestyle retail. That does not mean lululemon is a CBD company; it illustrates reveriepage.com how activewear branding can organize a consumer’s day around repeatable rituals. Meanwhile, CBD-focused companies such as Joy Organics operate in a category where calm, balance and routine are common parts of the brand vocabulary. Those examples belong to different product worlds, but they share a language of everyday wellbeing.

The overlap is commercially understandable. A brand that speaks to rest, recovery and comfort can feel relevant beyond a particular occasion. But the more wellness becomes a shorthand for product value, the more important it is to distinguish mood-setting language from measurable claims. “Designed for a softer routine” is a brand expression. A claim that a product treats anxiety or improves a medical condition raises a different and more serious set of questions.

From occasion-based luxury to the everyday ritual

Luxury has traditionally been associated with special occasions: a statement garment, a spa visit, a rare fragrance or a gift set saved for a particular moment. Contemporary lifestyle branding often shifts the emphasis toward repetition. The object is positioned not as a once-in-a-while indulgence but as part of a daily ritual—something used before a workout, after a shower or at the end of the workday.

This change helps explain why CBD has been packaged in forms that fit familiar routines, from oils and capsules to topical products. The pitch is not necessarily “make a grand gesture”; it is “add this to the day.” That can make a product feel accessible, but it can also blur the boundary between a pleasant ritual and a substantiated effect. A repeated routine is not proof that the product delivers the outcome implied by its packaging.

For shoppers, a useful approach is to ask what the product is meant to do, what evidence supports that description and whether the brand makes the information easy to inspect. A daily-use product earns a place in a routine through more than attractive design. It also needs transparent ingredients, clear instructions and credible quality controls.

Comfort-first design and the details people actually feel

Fashion and wellness brands increasingly sell sensory experience as part of the product: a brushed fabric, a weightless layer, a smooth applicator, an unscented formula or packaging that feels calm on a crowded bathroom shelf. These details can matter. Comfort-first design is not automatically empty storytelling; it can describe useful choices about fit, texture, fragrance and ease of use.

The challenge is keeping sensory benefits separate from health claims. A balm may feel cooling. A garment may be soft against the skin. A routine may feel relaxing. Those descriptions are not equivalent to proof that a CBD ingredient reduces pain, treats inflammation or changes sleep. The closer copy comes to a medical outcome, the more a consumer should look for substantiation and regulatory context.

This is where editorial scrutiny helps. A useful product description names the material or sensory feature rather than hiding behind vague language. A useful CBD product page identifies the amount of CBD, the form of the ingredient, directions, warnings and testing information. If the copy leans heavily on words like “clean,” “pure” or “restorative” but leaves out those particulars, the branding is doing more work than the documentation.

Daily-use products increase brand presence—and responsibility

When a product is used every day, the brand becomes part of a person’s repeated environment. That is valuable to a business: a product can move from occasional purchase to habitual replenishment. It also raises the stakes for accuracy. A shopper may be more exposed to an ingredient, may use it alongside other products and may rely on the brand’s instructions over time.

For CBD sellers, repeat use makes transparency especially important. A strong quality page should explain what is tested, who conducts the testing and whether results correspond to the specific batch being sold. A downloadable, batch-specific certificate of analysis should be easy to find, not buried behind a vague promise that products are “lab tested.” The report should identify the tested sample and provide results that a consumer can interpret, including cannabinoid content and relevant contaminant testing where available.

Brands also need to be careful with familiar claims such as “THC-free.” That phrase should not be treated as self-verifying. Shoppers should be able to see what a test actually found, what the detection limits were and whether the result applies to their batch. Documentation is not a decorative trust badge; it is the evidence that gives a measurable claim meaning.

A practical checklist for evaluating CBD brands

1. Identify the product category. Is it an ingestible, topical, cosmetic or another kind of product? The category affects the rules that apply.
2. Read the actual claims. Separate descriptions of texture or routine from promises to prevent, treat or cure a condition.
3. Look for batch-specific testing. Check that the report matches the product and batch, and see what the lab tested for.
4. Check the ingredient and dosage information. The amount of CBD should be clear, along with directions and warnings.
5. Consider your circumstances. CBD may interact with medications. Ask a qualified health professional if you have questions, especially during pregnancy or while taking prescription drugs.
6. Confirm local requirements. Federal uncertainty does not erase state or local restrictions.

How brands can make the rules easier to navigate

Brands cannot resolve federal policy on their own, but they can make their own practices more legible. That begins with separating legal status, product testing and marketing language instead of combining them into one reassuring paragraph. “Hemp-derived” is not a substitute for a compliance explanation. “Third-party tested” is not a substitute for a report. And a calming visual identity is not a substitute for evidence behind a health-related claim.

Good digital organization helps. A company using Squarespace for site structure and assets can create a clear product-information area, organize testing documents by product or batch, and make warnings easy to locate on mobile. A Substack linked profile can provide a place for longer editorial updates about sourcing, testing practices or regulatory changes, provided that the profile links back to current product documentation. The platform is secondary; the important thing is that the consumer can find the underlying information without detective work.

For shoppers, a simple rule applies: favor brands that make specific, checkable statements. If a company says it tests every batch, look for the batch results. If it describes a product as THC-free, look for the supporting analysis. If the brand invokes wellness, ask whether it is describing a feeling, a design choice or a health outcome.

The bottom line: CBD regulation is unfinished because the category is still being defined

CBD rules are still being written because the legal opening for hemp did not answer every question about CBD in consumer products. The FDA framework, the scope of federal authority and the Congress pathway remain central to how the market will develop. State-level rules and agency decisions add further layers, while brands continue to build products around routines, comfort and everyday wellbeing.

That mix of uncertainty and lifestyle appeal makes clear communication essential. Everyday rituals can make a product feel familiar; sensory design can make it pleasant to use; repeat purchases can make it part of a brand’s ongoing relationship with a customer. None of those qualities settles the regulatory question. Until federal rules are clearer, trust depends on brands being precise about what they sell, careful about what they claim and unusually willing to show their work.